Lenalidomide and metronomic melphalan for CMML and higher risk MDS: A phase 2 clinical study with biomarkers of angiogenesis  by Buckstein, Rena et al.
L
M
R
C
A
a
b
c
d
e
f
a
A
R
R
A
A
K
A
M
C
B
C
V
1
c
c
i
a
o
P
t
o
a
c
M
O
h
0Leukemia Research 38 (2014) 756–763
Contents lists available at ScienceDirect
Leukemia  Research
j ourna l h om epa ge: www.elsev ier .com/ locate / leukres
enalidomide  and  metronomic  melphalan  for  CMML  and  higher  risk
DS:  A  phase  2  clinical  study  with  biomarkers  of  angiogenesis
ena  Bucksteina,∗, Robert  Kerbelb, Matthew  Cheunga, Yuval  Shakedc, Lisa  Chodirkera,
hristina  R.  Leeb, Martha  Lenisd,  Cindy  Davidsona, Mary-Anne  Cussend, Marciano  Reise,
lden  Chesneye, Liying  Zhangd, Alexandre  Mamedovd,  Richard  A.  Wellsa,f
Department of Medical Oncology/Hematology, Odette Cancer and Sunnybrook Health Sciences Center, Toronto, Canada
Department of Medical Biophysics and Platform Biological Sciences, Sunnybrook Research Institute, Toronto, Canada
Department of Molecular Pharmacology, Rappaport Faculty of Medicine Technion – Israel Institute of Technology, Haifa, Israel
Department of Clinical Trials, Odette Cancer and Sunnybrook Health Sciences Center, Toronto, Canada
Departments of Pathology and Laboratory Medicine, Sunnybrook Health Sciences Center, Toronto, Canada
Department of Biological Sciences, Sunnybrook Research Institute, Toronto, Canada
 r  t  i  c  l e  i  n  f  o
rticle history:
eceived 9 January 2014
eceived in revised form 2 March 2014
ccepted 28 March 2014
vailable online 5 April 2014
eywords:
ngiogenesis
a  b  s  t  r  a  c  t
Metronomic,  low  dose  chemotherapy  may  have  anti-angiogenic  effects  and  augment  the  effects  of
lenalidomide  in  MDS  and  CMML.  We  evaluated  the  clinical  efﬁcacy,  tolerability  and  anti-angiogenic
effects  of  melphalan  2  mg  and  lenalidomide  10 mg  for 21  days/28  in  CMML  (n =  12)  and  higher  risk  MDS
(n  =  8) patients  in  a prospective  phase  II  study.  The  primary  endpoint  was  overall  response  and  sec-
ondary  endpoints  included  survival,  progression-free  survival,  toxicity  and  biomarkers  of angiogenesis.
The  median  age  was  73  years,  55%  were  pretreated  and  transfusion  dependent.  The  overall  response  rate
was  3(15%)  of  19  evaluable  patients  but 25% in  CMML  and  33%  in  pCMML.  Dose  reductions  and/or  delaysDS
MML
iomarker
irculating endothelial cells
EGF
were  common  due  to myelosuppression.  Transient  spikes  in circulating  endothelial  cells that  declined
below  baseline  were  seen  in responders  and  patients  with  CMML,  suggesting  anti-angiogenic  activity.
In  conclusion,  lenalidomide  and  metronomic  low  dose  melphalan  demonstrate  signals  of  clinical  and
possible  anti-angiogenic  activity  in  patients  with  pCMML  that require  future  validation.  This  trial  was
registered  at clinicaltrial.gov  under  #  NCT00744536.
© 2014  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND. Background
Myelodysplastic Syndromes (MDS) and chronic myelomono-
ytic leukemia (CMML) comprise a heterogeneous group of stem
ell disorders resulting in ineffective hematopoiesis and clonal
nstability. The clinical presentation is typically that of cytopenias
nd functional cell defects and the development of acute myel-
genous leukemia (AML) in approximately a third of patients [1].
atients with CMML  have monocytosis and may also have fea-
ures of myeloproliferative neoplasms including splenomegaly and
rgan inﬁltration with monocytes. Patients with higher risk MDS
s deﬁned by the International Prognostic Scoring System (IPSS) [2]
omprising 25–30% of cases, or higher risk CMML  deﬁned by the
D Anderson Scores [3,4] have shorter overall and leukemia-free
∗ Corresponding author at: Odette Cancer Center, 2075 Bayview Avenue, Toronto,
N  M4N3M5, Canada. Tel.: +1 416 480 5847; fax: +1 416 480 6002.
E-mail address: rena.buckstein@sunnybrook.ca (R. Buckstein).
ttp://dx.doi.org/10.1016/j.leukres.2014.03.022
145-2126/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unlicense  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
survivals. Aberrantly increased angiogenesis in the bone marrow
may be a factor contributing to disease progression. Bone mar-
row microvessel density increases as the blast percentage increases
[5] and this increase is associated with inferior survival. Vascu-
lar endothelial growth factor (VEGF), the major positive regulator
of angiogenesis, is present at increased concentrations in MDS
blood and marrow [5,6]. Recently angiopoietin 1 (Ang-1) overex-
pression was found to be associated with higher risk and higher
blast percentage MDS  and to correlate with the development of
AML. Furthermore, high levels of Ang-1 were predictive of shorter
overall survival independent of karyotype, IPSS and age [7]. It has
been hypothesized that these pro-angiogenic cytokines may  pro-
mote leukemia cell propagation and survival via both paracrine and
autocrine signaling [8]. Angiogenic factors may interact with other
mechanisms, including differentiation and apoptosis in CMML  and
MDS  [9,10]. By contributing to self- renewal of leukemia and MDS
progenitors and elaboration of inﬂammatory cytokines such as
tumor necrosis factor alpha (TNF-),  it is logical to speculate that
therapeutic targeting of angiogenesis may  improve hematopoiesis,
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
ia Res
d
r
t
b
a
c
p
n
m
l
p
r
d
t
f
t
b
i
b
t
e
c
u
t
a
t
a
w
p
t
m
a
e
i
h
n
m
t
2
2
t
r
b
p
W
s
c
o
e
(
2
n
r
m
O
(
8R. Buckstein et al. / Leukem
elay the transition to leukemia and improve survival in these high-
isk sub-groups.
There have been a limited number of largely negative clinical
rials of anti-angiogenic therapies in MDS/AML or CMML,  possi-
ly because the agents were tested as monotherapies in highly
dvanced disease. In a German, French and Belgian (GFM) clini-
al trial, bevacizumab in conventional dosing was tested in MDS
atients with excess blasts. Although the drug had pharmacody-
amic activity as reﬂected by reduced VEGF and bone marrow
icrovessel density, only 1/20 patients had a signiﬁcant hemato-
ogic response [11]. Minimal clinical activity was seen in another
hase 2 trial of SU5416, a ﬁrst generation small molecule VEGF
eceptor inhibitor for patients with refractory myeloproliferative
iseases although CMML  comprised only 18% of the total popula-
ion [12].
Low-dose, metronomic chemotherapy (LDMC) is a strategy
or optimizing the effects of chemotherapeutics by administering
raditional cytotoxic drugs (e.g.  melphalan, cyclophosphamide, vin-
lastine, etc.) at lower doses without prolonged rest periods. LDMC
s thought to inhibit tumor angiogenesis through multiple possi-
le mechanisms – by direct killing of activated endothelial cells in
he tumor neovasculature [13,14], inhibition of tumor cell HIF-1
xpression and by inhibition of circulating endothelial precursor
ells [15]. Other possible non-angiogenic mechanisms of activity
nder investigation include immunomodulation (with the deple-
ion of T regulatory cells and the upregulation of cytotoxic T cells)
nd cancer stem cell targeting [16,17]. Studies in animal models of
umors [13,14,18] have demonstrated that maximal inhibition of
ngiogenesis and tumor regression occurs when LDMC is combined
ith anti-angiogeneic drugs targeting the VEGF pathway. Recent
hase II and III clinical trial results provide further support for their
reatment combination [19,20].
Lenalidomide has clinical activity in non del5q MDS  [21] and one
echanism of action may  include its demonstrated anti-angiogenic
ctivity [22] through the inhibition of VEGF and TNF- induced
ndothelial cell migration and Akt phosphorylation [23].
Continuous oral low dose melphalan has demonstrated activ-
ty and safety in higher risk MDS  and AML  [24,25] particularly in
ypocellular variants.
This phase II study explored the efﬁcacy and safety of combi-
ation therapy with both lenalidomide and low dose continuous
elphalan in patients with CMML  or higher risk MDS  and examined
he effects on biomarkers of angiogenesis.
. Patients and methods
.1. Study design
This was  a single-arm, single center phase 2 prospective trial of combination
herapy with lenalidomide and melphalan in patients with CMML  1–2 or higher
isk (int-2 or high) MDS  deﬁned by the IPSS [2] or transfusion dependent MDS  with
last % ≥5. Patients had to demonstrate adequate hepatic and renal functions and
erformance status (ECOG ≤2). In patients with proliferative CMML-1 or 2 (pCMML,
BC  > 12 × 109/L), risk group was assigned using an MD  Anderson CMML  prognostic
coring system [3]. Patients could receive up to 12 cycles of lenalidomide 10 mg po
ombined with melphalan 2 mg  po daily for 21 days out of 28. Two  dose reductions
f  lenalidomide and melphalan were permitted (see online Appendix A).
Patients remained on study drugs until progression, death, unacceptable adverse
vent or 12 months. Patients were followed until progression, death or data lock
March 2013). All patients provided informed consent.
.2. Assessment of efﬁcacy
The primary endpoint was overall response rate as deﬁned by modiﬁed inter-
ational working group standardized response criteria which included complete
emission (CR), partial remission (PR), marrow CR (mCR) and hematologic improve-
ent (HI) [26]. The secondary endpoints were cytogenetic remission rates, safety,
S, PFS, and biomarkers of angiogenesis including circulating endothelial cells
CECs) and precursors (CEPs), plasma VEGF and VEGFR 1–2 levels.
Bone marrows for response assessments were performed days 1 of cycles 3, 5,
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2.3. Adverse event assessment
Adverse events were identiﬁed and graded 1–5 using Common Toxicity Criteria
v.  3.0. Hematologic toxicities were recorded throughout the study, and are reported
as  median percentage declines in absolute counts and increases in grade from base-
line  occurring during the ﬁrst 12 weeks of therapy.
2.4. Evaluation of angiogenesis
Soluble plasma VEGF, VEGFR1 and 2 levels were measured at baseline, day 1 of
cycles 1–3 and twice thereafter at intervals of 3 months, and at study discontinu-
ation. CECs and CEPs were measured at the same time points and enumerated as
previously described [27,28] (see online Appendix A).
2.5. Sample size and statistical analysis
The sample size for this study was based on Simon’s optimal two-stage design
(alpha = 0.05 and power = 80%) with 9 patients enrolled in the ﬁrst stage. The trial
would be terminated if 0 responses were observed during the ﬁrst stage. Otherwise,
an  additional 8 patients would be accrued in the second stage. The regimen would
be active if 2 or more responses were observed from 17 patients accrued. A total
of  20 patients were planned to accommodate for an anticipated 20% dropout rate.
Data were presented descriptively using median, interquartiles (IQR), and ranges
for continuous variables; using proportions for categorical ﬁndings. Overall Sur-
vival (OS) and Progression-free Survival (PFS) were presented using Kaplan–Meier
curves and log-rank test. To compare baseline biomarkers between groups of
patients, non-nonparametric median test was conducted. To assess for correlations
between selected biomarkers or blood counts, Spearman correlation coefﬁcients
were calculated with p-value < 0.05 considered statistically signiﬁcant. All results
were conducted using Statistical Analysis Software (SAS version 9.3 for Windows)
package.
3. Results
The study received local Institutional Review Board approval
and accrued between January 2008 and March 2011. This trial
was registered at http://www.clinicaltrials.gov/ as NCT00744536.
Twenty patients with histologically conﬁrmed CMML  or higher
risk MDS  were enrolled at the Odette Cancer Center for this study
(Table 1). A preponderance of patients enrolled in this study had
CMML  (n = 12, 60%) and 9/12 had a total leukocyte count greater
than 12 × 109/L. The median age was  73 years (range 52–87) and the
median time from MDS  diagnosis was 5.9 months (range 0.4–55).
The median blast percentage was 6% (1–18) and 55% were transfu-
sion dependent (TD) at enrollment. Thirty ﬁve percent had received
a prior erythropoietic stimulating agent (ESA), 30% prior hydrox-
yurea and 19% prior valproic acid. Of those classiﬁable by the IPSS,
58% had Int-2 and 42% had high-risk disease. For the 12 CMML
patients, the MD Anderson CMML  prognostic scores were primar-
ily intermediate-1 (42%) and Int-2 (50%) [3]. Sixty seven percent
of the 9 pCMML  patients (WBC > 12 × 106/l) had Int-2 risk scores.
Patients received a median of 4 cycles (range 1–12) with a median
cycle length of 30 days (range 20–63). The median follow up was
8 months (range (1–46) and median time on study was  5 months
(range 1–12).
3.1. Response
19/20 patients were evaluable for response assessment
(Table 2). One patient achieved a marrow CR at 68 days, 1 hemato-
logic improvement (HI)-PLT at 63 days and 1 HI-erythroid at 147d
for a total response rate of 15%. All three responses were seen in
patients with proliferative CMML-1 (median number of cycles = 9,
IQR 4–9). Nine patients (47%) had stable disease (median # cycles 6,
IQR 4–9). Four patients (21%) were graded as failures due to wors-
ening cytopenias without progression or death on study (median
number of cycles = 2.5, IQR 1–4) and 3 patients (16%) had progres-
sive disease (median number of cycles = 3, IQR 3–3). The 9 patients
with pCMML  had a median WBC  of 46 × 109/L (range 19–312) at
baseline that declined by 82% over the ﬁrst 3 cycles. Similarly, the
LDH, which was elevated at baseline (313 IU/L), declined by 37% to
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 normal level (196 IU/L) after 3 cycles (Fig. 1). One notable patient
ith pCMML-1 who had initially presented with rapidly increasing
eukocytosis, red cell and platelet transfusion dependence, symp-
omatic pleural effusions and peripheral edema had resolution of
er effusions and edema by cycle 4 and became red cell transfu-
ion independent by 147 days. She remained alive, effusion/edema
ree with a normal WBC  and LDH at a follow up of 3.9 years from
nrollment. She remained off all therapy, red cell and platelet trans-
usion independent despite only receiving 9 months of treatment.
n contrast, another patient with pre-treated pCMML-1 had a dra-
atic decrease in his WBC  (from 312 to 78 × 109/L) and LDH (from
00 to 450 IU/L) after 1 cycle of therapy but remained persistently
ymptomatic with unremitting ascites and peripheral edema that
orsened markedly on the 1-week drug holiday. As a result, he was
aken off study after 3 cycles, despite achieving a HI-P.
Only 1 patient with stable disease completed all 12 cycles and
 patient became red cell transfusion independent on study. The
easons for premature discontinuation included death (n = 3), pro-
ressive disease (n = 5) and toxicity (n = 11).
.2. Survival
In total, 5 progressed and three died on study. At follow-up,
9 patients have died: 10 due to progressive disease and 9 from
ther causes (myocardial infarction (n = 1), congestive heart fail-
re (n = 3), pneumonia (n = 2), post hip surgery complication (n = 1),
iver failure (n = 1) and unknown (n = 1). The median overall and
rogression-free survivals were 8.5 months (95% CI 5.9–12.7) and
.7 months (95% CI 4.2–12.3) respectively and are depicted in Fig. 2.
.3. Assessment of safety
Despite a high rate of baseline cytopenias (Table 2B) worsening
ematologic toxicity was prevalent. Within the ﬁrst 12 weeks of
herapy, 20% grade 3 and 45% grade 4 neutropenia, 10% grade 3
nd 75% grade 4 thrombocytopenia were documented (Table 2C).
hile day 1 cell counts for subsequent cycles often improved com-
ared with nadirs, 45% and 60% had grades 3–4 neutropenia and dehydrogenase (IU/L). IQR: Interqurtile range.
thrombocytopenia respectively at these time points. This repre-
sented a worsening in grade neutropenia and thrombocytopenia
(compared with baseline) for 40% and 55% of patients. As a result,
dose delays and/or reductions were common. Of the 16 patients
that had 2 or more cycles, 9/16 had a lenalidomide dose reduction
by or during cycle 3:6/9 to 5 mg  daily and 3/9 to 5 mg alternate
days. In two additional patients dosage was reduced to 5 mg daily
after cycle 4. Similarly, 8/16 patients had a melphalan dose reduc-
tion to 2 mg  alternate days by or during cycle 3, and by cycle 5, 4/8
were dose reduced, 2 to 2 mg  alternate days and 2 to 2 mg  twice
weekly. Four patients discontinued therapy within the ﬁrst cycle
for toxicity or disease progression and 7 patients by cycle 3. Three
patients died on study, 1 from transfusion associated circulatory
overload (TACO) post red cell transfusion in cycle 1, 1 from pneu-
monia in cycle 1 and 1 from progressive disease and blast crisis
post cycle 9. No death was  felt to be directly treatment related.
The grade 3–4 non-hematologic toxicities (and attributions)
are summarized in Table 2A. The most common non-hematologic
toxicities were infection (pneumonia (n = 2), febrile neutropenia
(n = 3), cellulitis (n = 1)), neurologic (syncope n = 2, ischemic event
n = 1), and cardiac (atrial ﬁbrillation (n = 1), congestive heart failure
(n = 1) and TACO (n = 1, grade 5). There was  1 episode of grade 3
epistaxis.
3.4. Biomarkers
Angiogenesis related biomarkers were available in 19 patients
at baseline, 16 patients at cycle 2 day 1, 15 patients at cycle 3
day 1 with reducing numbers thereafter due to patient attrition
(Fig. 3). CEPs were too infrequent to measure for most patients and
are not reported. End of study (EOS) readings were available in 5
patients with either response or stable disease at a median time of
37 days (range 28–50 days) post last dose. When plotted over time
for all patients, there were no discernable declines in serum VEGF
or circulating VEGFR1 or VEGFR2 although an apparent transient
spike in CECs was noted during the ﬁrst cycle that then reverted
to baseline or declined by cycle 6 (data not shown). Sample sizes
are generally too small to detect statistically signiﬁcant differences
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n the changes between responders (n = 3), stable disease (n = 9)
nd patients with progressive disease and failure (n = 6) but it is
nstructive to observe any trends according to response (Fig. 3a–c).
esponding patients had higher levels of baseline CECs compared
ith non responders (10.35 cells/l, IQR 6.35–187 versus 4.48
ells/l, IQR 2.24–13.8, p = .06). Responders also appeared to have
 19 fold spike in total (primarily viable) CECs after the ﬁrst cycle
f therapy (from 10.35 cells/l, IQR 6.3–187.2 to 193.7 cells/l, IQR
8.9–268.4) before reverting back to baseline and declining in sub-
equent cycles. This compares with a 6 fold spike in total CECs after
he ﬁrst cycle in patients with progressive disease or failure (from
.8 cells/l, IQR 3.4–4.4 to 23.9 cells/l, IQR 1–46). Similarly, in
MML  we also documented transient spikes in total CECs after cycle
 (from 6.67 cells/l, IQR 3.7–16.2 to 24 cells/l, IQR 5.2 to 50) that
radually declined by 86% at cycle 6, only to increase again toward
he end of study drugs (Fig. 3d–e).
The median baseline VEGF levels were higher for CMML  than
or non-CMML patients (43.45 versus 26.5 pg/ml) but they were
ot statistically different (p = 0.22). Baseline CECs were signiﬁcantly
igher in the CMML  patients compared with the other WHO  MDS
ubtypes (6.67 versus 3.45 cells/l, p = .03), (Table 3). In the CMML
atients, VEGF, sVEGFR1, sVEGFR2 and CEC were not signiﬁcantly
orrelated with the monocyte count, total WBC  or LDH.
CECs were weakly correlated with sVEGFR1 at baseline (r = 0.45,
 = .05) and with serum VEGF on day 1 cycle 2 (r = 0.68, p = .02).rogression-free survival.
4. Discussion
Metronomic chemotherapy is under active investigation in the
clinic, especially for the treatment of solid tumors. As recently
reviewed, there are more than 80 published phase 2–3 studies
encompassing 3688 patients with a variety of cancers that have
demonstrated the clinical beneﬁts of LDMC. The most commonly
used drugs are cyclophosphamide, and oral 5-FU (5 ﬂuorouracil)
pro-drugs capecitabine or UFT (tegafur-uracil). LDMC is frequently
combined with other therapies (64%) [29]. Anti-angiogenic ther-
apy in general and LDMC speciﬁcally have been infrequently
evaluated in blood cancers but show promise in the lymphoid
neoplasms, particularly with the drug cyclophosphamide [30–32].
The LDMC/anti-angiogenic ﬁeld was recently bolstered by the pos-
itive results of the CAIRO3 – a clinical trial of the Dutch Colorectal
Cancer Group. CAIRO3 demonstrated a signiﬁcant PFS beneﬁt to
maintenance treatment with bevacizumab + oral daily low dose
capecitabine in patients with metastatic colorectal carcinoma [20].
Before azacitidine was available there were limited therapeutic
options for patients with CMML  and higher risk MDS. Building
on our local experience with metronomic cyclophosphamide and
celecoxib in relapsed or refractory aggressive lymphomas [31]
we chose to evaluate the efﬁcacy, safety and anti-angiogenic
activity of metronomic melphalan and lenalidomide in CMML and
MDS  patients. During the course of the study, azacitidine became
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Fig. 3. (A) CEC according to response. (B) VEGF according to response. (C) VEGFR2 according to response. (D) CEC according to CMML  or not. (E) VEGF according to CMML
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vailable for int-2 and high risk MDS  and explains the predomi-
ance of CMML  patients on this study.
To our knowledge, this is the ﬁrst clinical trial to evaluate LDMC
s possible anti-angiogenic therapy in CMML  and MDS. We  chose
he immunomodulatory drug lenalidomide because it is modestly
ctive as monotherapy in non-del5q MDS  [21] and in higher risk
el5q MDS  [33] even after azacitidine failure [34]. One mechanism
f action in non-del5q MDS  may  include the inhibition of angiogen-
sis [22,23]. We  chose to partner lenalidomide with low continuous
ose melphalan because of its demonstrated activity and safety in
igher risk MDS  and AML  [24,25]. We  hypothesized that when used
n such a metronomic schedule this drug may  be functioning in part
ia anti-angiogenic mechanisms.In this study, we found a modest overall response rate of
5%, and a response rate of 25% in CMML  overall (3/12) and 33%
n proliferative CMML  (3/9). Our patients experienced signiﬁcant
yelosuppression at our starting doses of melphalan 2 mg  od andascular endothelial cell growth factor. VEGFR2: Vascular endothelial growth factor
lenalidomide 10 mg  od for 21d/28 schedule. This necessitated drug
reductions and dose delays in the majority of the patients within
2 cycles and 5 patients came off study early for thrombocytopenia.
While four patients discontinued treatment within 1 treatment
cycle due to death, disease progression or severe pancytopenia, it is
often difﬁcult to ascribe worsening blood counts to drug toxicity or
natural history in advanced pre-treated MDS  and CMML.  Our expe-
rience is consistent with that observed in higher risk del5q MDS
where lenalidomide monotherapy was  also associated with sig-
niﬁcant myelosuppression and adverse events necessitating dose
reductions to 5 mg/day in 72% and discontinuation after only 1 cycle
in 31% [33].
We chose to include CMML  in our patient population because
there were limited therapeutic options at the time. CMML  is now
a distinct entity deﬁned in the WHO  as an MDS/MPN, not strictly
MDS. It is classiﬁed as CMML-1 or 2 according to blast percentage
in the bone marrow and peripheral blood and has its own clinical
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Table  1
Baseline characteristics n = 20.
Baseline characteristics N (%)
Age at consent (year)
Median (range) 73 (52–87)
Gender
Male/female 13/7 (65%/35%)
WHO  subtype
RCMD-RS 1 (5.00%)
RAEB-1 2 (10.00%)
RAEB-2 5 (25.00%)
CMML-1 10 (50.00%)
CMML-2 2 (10.00%)
IPSS risk group
(n = 11
evaluable,
includes 3
CMML  with
low WBC)
Int-2 MDS  9 (82.00%)
High risk MDS 2  (18.00%)
IPSS – MD Anderson CMML  (n = 12)
Low 1 (8.33%)
Int-1 5 (41.67%)
Int-2 6 (50.00%)
Time from diagnosis (months)
Median (range) 5.9 (0.4–55.1)
Hgb
Median (range) 93.5
(68.0–122.0)
ANC (absolute neutrophils count)
Median (range) 5.2 (0.3–124.7)
Platelets
Median (range) 56 (7–621)
Transfusion dependence at baseline
TI 9 (45.00%)
TD  11 (55.00%)
Previous therapy (n = 12)
ESA 7 (58.33%)
Lenalidomide 0 (0%)
Immunosuppressive therapy 1 (8.33%)
Hydroxyurea 6 (50.00%)
Valproic acid 2 (16.67%)
Bone marrow blast (%)
Median (range) 6 (1–18)
Karyotype
Good risk 12 (66.6%)
Intermediate risk 2 (11.11%)
Poor risk 4 (22.2%)
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Table 2
Adverse events.
2A
Non-hematologic toxicities
Grades 3–4 on
study
n (%) Possible/probably/deﬁnitely
related to protocol therapy n
(%)
Infection 6 (30%) 6 (30%)
Neurological 3 (15%) 3 (15%)
Cardiac (CHF, arrhythmia) 3 (15%) 0 (0%)
Endocrine 1 (5%) 1 (5%)
Hemorrhage/bleeding 1 (5%) 1 (5%)
Pain 1 (5%) 1 (5%)
Constitutional symptoms 1 (5%) 0 (0%)
Gastrointestinal 1 (5%) 0 (0%)
Musculoskeletal/soft/tissue 1 (5%) 0 (0%)
Pulmonary 1 (5%) 0 (0%)
2B Hematologic toxicity grades@ baseline (n = 20)
1 2 3 4
Anemia 7 (35%) 9 (45%) 3 (15%) 0 (0%)
Leukocytes 1 (5%) 2 (10%) 3 (15%) 0 (0%)
Neutrophils 2 (10%) 1 (5%) 2 (10%) 3 (15%)
Platelets 6 (30%) 3 (15%) 6 (30%) 2 (10%)
2C Hematologic toxicity grades on study (n = 20) (ﬁrst 12 weeks)
1 2 3 4
Anemia 4 (20%) 5 (25%) 8 (40%) 3 (15%)
Leukocytes 3 (15%) 3 (15%) 5 (25%) 4 (20%)
Neutrophils 0 (0%) 3 (15%) 4 (20%) 9 (45%)
Platelets 1 (5%) 2 (10%) 2 (10%) 15 (75%)
Grade 3–4 non hematologic toxicities on study and relatedness to therapy. 2B: AllHO: World health organization, IPSS: International prognostic scoring system,
gb: Hemoglobin, TI: Transfusion independent, TD: Transfusion dependent.
rognostic scoring systems, with most systems reporting infe-
ior survival for proliferative forms deﬁned by a WBC  > 12 × 109/L
3,35,36,37]. There are a limited number of published case reports
r clinical trials discussing the activity of lenalidomide in CMML
s monotherapy [38] or in combination with bortezomib [39].
hile the hypomethylating agents azacitidine and decitabine are
pproved for CMML  based on activity observed in phase 2 and 3
rials, CMML  (particularly pCMML) is often underrepresented in
uch trials [40–42]. Our study was conceived before the availabil-
ty of HMA  therapy for CMML  in Ontario, which has subsequently
ecome available but restricts reimbursement to patients with
BC  < 13 × 109/L, based on AZA-001 inclusion criteria [40]. Sim-
larily, the EMA (European Medical Agency) has restricted the
pproval of azacitidine for the treatment of CMML-2 in the absence
f myeloproliferative aspects, which restricts access to only 10–20%
f patients. This leaves hydroxyurea as the primary option for
atients with proliferative CMML  which is not always long-lasting
or effective. In addition, the OS after azacitidine failure is short [43]
herefore alternative therapies are needed in these circumstances.
It is interesting to note that the 3 responding patients all had
CMML  (out of 9 total, ORR 33%) and remained on drug for a mediangrade hematologic toxicities at baseline. 2C: All grade hematologic toxicities on
study during ﬁrst 12 weeks.
of 9 cycles suggesting a possible signal of activity and tolerability
unique to this histology. The anti-proliferative effects of lenalido-
mide and melphalan in CMML  are also evident in the declines seen
in LDH, WBC  and monocyte count (Fig. 1). The higher baseline levels
of VEGF and CEC’s in CMML  patients compared with other MDS  sub-
types may  point to higher levels of angiogenesis driving this disease
as previously observed [6,44,45] and a potential ‘druggable’ target
for appropriately selected patients.
Mature circulating endothelial cells (CECs) are in most cases
apoptotic in healthy subjects and more viable in cancer patients,
and represent an indirect marker of vessel damage and/or turnover
and remodeling associated with angiogenesis [46]. CECs are signif-
icantly increased in different types of cancer [47] but because they
are rare events, they need to be enumerated in dedicated labo-
ratory with experienced personnel that use rigorous, robust and
validated multiparametric procedures [48]. Changes in CECs and or
CEP levels during therapy have been found to correlate with clinical
outcomes of response and/or survival in 5 studies, but baseline lev-
els have been inconsistently predictive of response in clinical trials
of anti-angiogenic agents [49]. In one study, a CEC count of > 11uL
after 2 months was predictive of improved overall and disease-free
survival and the increase was attributed to an increased fraction of
apoptotic CEC’s [27]. In that study, a signiﬁcant decline in VEGF-A
levels after 2 months of therapy was associated with a signiﬁcantly
improved time to progression. In the current study, the increase
in CEC values observed prior to cycle 2 in responding patients and
those with CMML  was  primarily of viable cells. This is consistent
with results from a preclinical model [50], in which a maximally
tolerated dose (MTD) regimen caused short-term suppression of
viable CECs and CEPs immediately after drug administration, fol-
lowed by a robust rebound effect leading to an increased number
of viable cells prior to the next cycle. The declines we observed
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Table 3
Biomarkers at baseline (cycle 1 day 1) according to response or histology.
N CEC (IQR) VEGF (IQR) VEGFR1 (IQR) VEGFR2 (IQR)
Response 3 10.35 (6.3–187) 47.7 (30.1–61.4) 125.0 (106.7–257.6) 7534 (6418.4–7640.9)
PD  + Failure 6 3.7 (3.4–4.5) 17.96 (15.1–26.5) 100.2 (78–105.7) 7557.9 (7040–7895.8)
SD  9 5.3 (2.2–13.8) 39.9 (21.2–80.7) 104.6 (93.6–119.2) 7534 (6418.4–7640.9)
CMML 12 6.7 (3.7–16) 43.4 (25.9–71.6) 106.9 (100.2–127) 7418.9 (6736.1–7916.8)
MDS  (non-CMML) 7 3.4 (0.2–4.65) 26.5 (15.4–37.8) 95.1 (78–105.7) 7875.2 (7040.7–8244.7)
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pD: Progressive disease, SD: Stable disease, CMML:  Chronic myelomonocytic leukem
ile  range, VEGF: Vascular endothelial growth factor (pg/ml), VEGFR-1: Vascular en
eceptor 2(pg/ml).
n subsequent cycles in responding patients and those with CMML
who remained on drug long enough) may  have reﬂected the almost
biquitous dose reductions in lenalidomide and melphalan per-
aps transforming lenalidomide and metronomic melphalan into
nti-angiogenic rather than MTD  cytotoxic agents. Higher levels of
aseline CECs as biomarkers predictive of response to this regimen
ill need validation in more patients.
Numbers of viable CEC’s and CEP’s are increased in the periph-
ral blood of patients with advanced MDS  and AML, and patients
ith higher levels of CECs also showed increased microvessel den-
ity, a surrogate marker of increased angiogenesis [51]. In a phase
 study of ABT-751, a novel microtubule inhibitor, decreases in
EC numbers correlated with declines in WBC  counts [52] although
his was not our experience. Given that CEC are directly calculated
ased on the total WBC, this non-signiﬁcant correlation supports
he notion that any declines in CEC were related to other factors
nd not just non-speciﬁc myelosuppression.
Although early reports described an association between
ncreased angiogenesis and higher risk MDS  subtypes, recent ﬁnd-
ngs have shown higher CEC levels in patients with lower risk MDS
nd have established negative correlations between CEC number
nd IPSS risk categories; similarily, microvessel density was  most
ositively correlated with CEC number in patients with low-risk
DS  [53]. Congruently, serum VEGFR2 was signiﬁcantly higher in
he lower IPSS risk classes [51]. It has been hypothesized that the
eed for angiogenic support to the outgrowth of neoplastic cells
ay  be more important in earlier stages of the disease than in
ater stages in which other pathogenic factors may  play a more
igniﬁcant role [51,53]. In light of this, the optimal histologic MDS
ubtypes in which to test the clinical efﬁcacy of anti-angiogenic
gents remains unclear but may  be in fact lower risk disease.
The limitations of this study include the small overall and sub-
roup sample sizes and the fact that one cannot determine if the
ctivity seen is primarily attributable to lenalidomide, melpha-
an or the combined approach. Nevertheless, in past pre-clinical
13,14,18] tumor models and clinical studies [54], combining 2 or
 therapies with presumed ‘anti-angiogenic’ activity was needed
or maximal therapeutic beneﬁt. The combination of lenalido-
ide with azacitidine in MDS  may  be superior to azactidine
onotherapy and is currently being tested in a controlled inter-
roup trial led by SWOG in higher risk MDS  and CMML  [55]
http://www.clinicaltrials.gov/: NCT01522976).
. Conclusions
Metronomic low dose melphalan combined with lenalidomide
s inactive in higher risk MDS  and poorly tolerated. There is a
ignal of moderate clinical activity in patients with proliferative
MML  (a form of MDS/MPN). While the mechanism of action may
e primarily cytotoxic, the inhibition of angiogenesis cannot be
xcluded as a contributing factor. This requires further testing and
alidation in a larger more homogeneous population. For future
tudies, recommended starting doses would be lenalidomide 5 mg
o daily and melphalan 2 mg  po alternate days for 21 days/28.S: Myelodysplastic syndrome, CEC: Circulating endothelial cells/l, IQR: Interquar-
lial growth factor receptor 1(pg/ml), VEGFR-2: Vascular endothelial growth factor
Easier to measure biomarkers are needed to identify appropriate
candidates for such therapies.
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